Cargando…

Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update

Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with the introduction and validation of noninvasive tests (NITs) to evaluate advanced fibrosis, and the direct-acting antiviral agents for treatment of chronic hepatitis C virus (HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bojanic, Kristina, Bogojevic, Mirta Sudaric, Vukadin, Sonja, Sikora, Renata, Ivanac, Gordana, Lucic, Nikola Raguz, Smolic, Martina, Tabll, Ashraf A., Wu, George Y., Smolic, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412701/
https://www.ncbi.nlm.nih.gov/pubmed/37577224
http://dx.doi.org/10.14218/JCTH.2022.00365
Descripción
Sumario:Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with the introduction and validation of noninvasive tests (NITs) to evaluate advanced fibrosis, and the direct-acting antiviral agents for treatment of chronic hepatitis C virus (HCV), the role of NITs have become even more complex. There is now need for longitudinal monitoring and elucidation of cutoff values for prediction of liver-related complication after sustained virological response. The aim of this report is to provide a critical overview of the various NITs available for the assessment of liver fibrosis in HCV patients.